Product news

Share this article:
Sanofi-Aventis and Bristol-Myers Squibb said the FDA Administration has approved a supplemental new drug application for a 300 mg tablet of the antiplatelet drug Plavix (clopidogrel bisulfate). The Plavix 300 mg tablet will facilitate the use of the FDA approved loading dose for appropriate acute coronary syndrome patients as soon as possible after hospital admission.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters